Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ACTIVEPORT GROUP LTD Director's Dealing 2025

Dec 21, 2025

64452_rns_2025-12-21_4db884d7-ca0c-43f3-befb-ee6faf0be53d.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity ActivePort Group Ltd
ABN 24 636 569 634

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Christopher Daly

Date of last notice 28 November 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Registered holders are Claude L. Daly &
Sons Pty Ltd A/C> and Ulster Capital Pty Ltd Super Fund A/C>. Christopher Daly is a
director and shareholder of both Claude
L. Daly & Sons Pty Ltd and Ulster Capital
Pty Ltd and a potential beneficiary of both
the Chris Daly Family Trust and the
Ulster Super Fund.
Date of change 18 December 2025
No. of securities held prior to change 8,525,014 ordinary shares, 250,000 options
expiring on 30 November 2026, 732,004
options expiring on 27 November 2027,
300,000 Class H ZEPOs, 300,000 Class I
ZEPOs and 400,000 Class J ZEPOs.
Class Options exercisable at $0.04 and expiring
on 31 January 2028
Number acquired 1,705,001
Number disposed Nil.
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$Nil.
No. of securities held after change 8,525,014 ordinary shares, 1,705,001 options
expiring on 31 January 2028, 250,000
options expiring on 30 November 2026,
732,004 options expiring on 27 November
2027, 300,000 Class H ZEPOs, 300,000
Class I ZEPOs and 400,000 Class J ZEPOs.
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Bonus options issued by the Company pro-
rata to all shareholders.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above No. traded during a[+] closed period where prior written clearance was required?

  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

If so, was prior written clearance provided to allow the trade to
proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A

Dated: 22 December 2025

  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3